Dr. Brandon Zipp is the Director of Research & Development and a Scientific Co-founder of Vitality Biopharma, Inc. He is a developer and inventor of the company’s cannaboside compounds, a class of cannabinoid compounds that have been modified through enzymatic glycosylation, and which enables targeting to the gastrointestinal tract. He has diverse training in biochemistry, molecular biology, and fermentation, combined with 15 years of research experience with plant glucosyltransferases, the enzymes that enable production of cannabosides. Dr. Zipp received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis in 2013.
Δ9-Tetrahydrocannabinol (THC) is a promising candidate for treatment of gastrointestinal (GI) conditions, including inflammatory bowel disease (IBD). The use of THC is limited today in certain patient populations such as pediatrics by its psychoactivity. To address this limitation, Vitality Biopharma has developed a class of cannabinoid prodrugs called cannabosides that act enable targeted delivery to the colon. VBX-100 is a THC prodrug that is being developed for IBD and other gastrointestinal conditions, and which has shown to be effective for treatment of preclinical models of colitis. VBX-100 and other cannabosides represent a new strategy for localized delivery of cannabinoids to enable more widespread use in adult and pediatric populations while avoiding psychoactivity and the adverse systemic effects of existing immunosuppressive IBD therapies..